POPULARITY
5 episodes with human trial
6 episodes with human trial
2 episodes with human trial
2 episodes with human trial
2 episodes with human trial
Today on Online for Authors, guest-host Carole O'Neill interviews Audrey Gale, author of the book The Human Trial. Audrey Gale long dreamed of being a writer, but never anticipated the circuitous road she'd take to get there. After twenty-plus years in the banking industry, she grew tired of corporate gamesmanship and pursued her master's in fiction writing at the University of Southern California. Her first novel, a legal thriller entitled The Sausage Maker's Daughters, was published under the name A.G.S. Johnson. The novel explores one woman's struggle to find her place amidst the upheaval of the radical 1960s. Her second, The Human Trial, is the first book in a medical-thriller trilogy inspired by Gale's own experiences with the gap between traditional medicine and approaches based on the findings of the great physicists of the 20th Century, like Einstein and Bohr. Both The Sausage Maker's Daughters and The Human Trial incorporate Gale's fascination with historical and scientific research, and always with women finding their places. Gale lives in Los Angeles with her husband and dogs where she is found hiking the Santa Monica Mountains every chance she gets. In her book review, Carole stated that The Human Trial showed that a small number of high school students graduate early and get accepted into a college program of their dreams. Very few graduate high school at 16 years old and go on to get a full-ride at Harvard University. However, Randy Archer, the son of a steel-mill worker in Pennsylvania, does just that. Audrey, the author of The Human Trial, takes you back to the 1920s, against the backdrop of The Great Depression, and introduces us to Archer as he is still living at home with his father and older brothers. They all expect him to follow them to a life in the steel mill. He has another idea, but no financial way to fulfill that dream. Gale describes how Archer defies the odds, with the help of his high school counselor and her friend at Harvard. She convinces Archer he will be mentored alone the way to a degree at the prestigious university unavailable to many. During his years as a graduate student studying to become a pathology researcher, he meets a physics student, Adam Wakefield, working on his PhD. He's developed a much-advanced microscope which allows the two students to discover a way to offer a non-traditional healing method to terminal patients. There is, of course, a love interest that Archer can't quite understand. Why such a beautiful girl from Boston's Beacon Hill would be interested in him, stymies him. Gale keeps you believing they will make the perfect marriage, or will they? The Human Trial has something for everyone: medical science, academic scheming, blue-collared families vs. Boston Brauhmans, and an impossible secret discovery everyone wants a piece of. This is a book that will keep you pulling for the underdog until the final pages. Subscribe to Online for Authors to learn about more great books! https://www.youtube.com/@onlineforauthors?sub_confirmation=1 Join the Novels N Latte Book Club community to discuss this and other books with like-minded readers: https://www.facebook.com/groups/3576519880426290 You can follow Author Audrey Gale Website: https://audreygaleauthor.com/ FB: @Audrey Gale Author IG: @audreygaleauthor Purchase The Human Trial on Amazon: Paperback: https://amzn.to/3DquTdM Ebook: https://amzn.to/4hgoaRm Teri M Brown, Author and Podcast Host: https://www.terimbrown.com FB: @TeriMBrownAuthor IG: @terimbrown_author X: @terimbrown1 Want to be a guest on Online for Authors? Send Teri M Brown a message on PodMatch, here: https://www.podmatch.com/member/onlineforauthors #audreygale #thehumantrial #suspense #historicalfiction #terimbrownauthor #authorpodcast #onlineforauthors #characterdriven #researchjunkie #awardwinningauthor #podcasthost #podcast #readerpodcast #bookpodcast #writerpodcast #author #books #goodreads #bookclub #fiction #writer #bookreview *As an Amazon Associate I earn from qualifying purchases.
In this episode, we sit down with Audrey Gale to discuss her latest novel, The Human Trial. As the second release of her medical-thriller trilogy, this book explores the gap between traditional medicine – while incorporating the findings of the great physicists of the 20th Century… Audrey has always dreamed of becoming an author. Now that this dream has become a reality, she is on a mission to flush out her fascination with historical and scientific research in a thoughtful and engaging way. Tune in now to learn about: The premise of The Human Trial, and what led Audrey to write it. Challenges that can arise while writing a novel. The power of holistic medicine. Other novels that Audrey is looking forward to writing. Want to find out more about Audrey and her work as an author? Click here now! Episode also available on Apple Podcasts: apple.co/30PvU9C
Thank you for joining us on todays podcast where we share space with Audrey Gale and discuss her book "The Human Trial". Where you can find us: daughters.moon.podcast@gmail.com YouTube – Daughters of the Moon Podcast IG @daughtersofthemoonpodcast Facebook - Daughters of the moon podcast https://daughtersmoonpodca.wixsite.com/mysite Listen to us on any of the Podcast Platforms. Information about guest: audreygaleauthor.com Instagram/Facebook audreygaleauthor TikTok audrey.gale Please like, share, follow and subscribe to our podcast. We would really love a positive review, as this helps us to grow our podcast and continue to bring you amazing content. If you would like to be on our podcast, please contact us to let us know what you would like to share with our followers and us. Our guests and topics are for informational purposes and may not align with everyone. We respectfully acknowledge the land on which we live, and work is Treaty 6 Territory, the traditional lands of the indigenous and the Metis People. For as long as the sun shines, the rivers flow, and the grass grows, this land will be recognized as Treaty 6 Territory.
Audrey Gale long dreamed of being a writer, but never anticipated the circuitous road she'd take to get there. After twenty-plus years in the banking industry, she grew tired of corporate gamesmanship and pursued her master's in fiction writing at the University of Southern California. Her first novel, a legal thriller entitled The Sausage Maker's Daughters, was published under the name A.G.S. Johnson. The novel explores one woman's struggle to find her place amidst the upheaval of the radical 1960s. Her second, The Human Trial, is the first book in a medical-thriller trilogy inspired by Gale's own experiences with the gap between traditional medicine and approaches based on the findings of the great physicists of the 20th Century, like Einstein and Bohr. “My hope for “The Human Trial” is that minds will be opened to new possibilities which have been successfully blocked for almost a century,” says Gale. ”Assuming the discoverers had what they'd tested and believed they had, millions of people have died unnecessarily in that time. I hope readers will realize that they must be their own demanding advocates within our healthcare system. We must all ask questions, demand answers and proof, read everything, talk to everyone, compare responses. Most of all I hope that someone in the position to carry forward this science will pick up the mantle and bring its benefits to all of life. The second installment in The Human Trial trilogy is in the works and Gale indicates it will carry on investigating the suppression of life-saving science. Both The Sausage Maker's Daughters and The Human Trial incorporate Gale's fascination with historical and scientific research, and always with women finding their places. Gale lives in Los Angeles with her husband and dogs where she is found hiking the Santa Monica Mountains every chance she gets. For more, visit http://audreygaleauthor.com/. Book The Human Trial, Books Fluent (September 21, 2023) Available from Amazon.com for $16.99 in trade paperback, $5.99 in ebook/Kindle, and audio $19.95. Website http://audreygaleauthor.com/. Social Media Instagram: https://www.instagram.com/audreygaleauthor/ Facebook: https://www.facebook.com/audreygaleauthor Twitter/X: https://twitter.com/TheAudreyGale
Audrey Gale long dreamed of being a writer, but never anticipated the circuitous road she'd take to get there. After twenty-plus years in the banking industry, she grew tired of corporate gamesmanship and pursued her master's in fiction writing at the University of Southern California. Her first novel, a legal thriller entitled The Sausage Maker's Daughters, was published under the name A.G.S. Johnson. The novel explores one woman's struggle to find her place amidst the upheaval of the radical 1960s. Her second, The Human Trial, is the first book in a medical-thriller trilogy inspired by Gale's own experiences with the gap between traditional medicine and approaches based on the findings of the great physicists of the 20th Century, like Einstein and Bohr. “My hope for “The Human Trial” is that minds will be opened to new possibilities which have been successfully blocked for almost a century,” says Gale. ”Assuming the discoverers had what they'd tested and believed they had, millions of people have died unnecessarily in that time. I hope readers will realize that they must be their own demanding advocates within our healthcare system. We must all ask questions, demand answers and proof, read everything, talk to everyone, compare responses. Most of all I hope that someone in the position to carry forward this science will pick up the mantle and bring its benefits to all of life. The second installment in The Human Trial trilogy is in the works and Gale indicates it will carry on investigating the suppression of life-saving science. Both The Sausage Maker's Daughters and The Human Trial incorporate Gale's fascination with historical and scientific research, and always with women finding their places. Gale lives in Los Angeles with her husband and dogs where she is found hiking the Santa Monica Mountains every chance she gets. For more, visit http://audreygaleauthor.com/. Book The Human Trial, Books Fluent (September 21, 2023) Available from Amazon.com for $16.99 in trade paperback, $5.99 in ebook/Kindle, and audio $19.95. Website http://audreygaleauthor.com/. Social Media Instagram: https://www.instagram.com/audreygaleauthor/ Facebook: https://www.facebook.com/audreygaleauthor Twitter/X: https://twitter.com/TheAudreyGale
Storycomic Presents: Interviews with Amazing Storytellers and Artists
#AudreyGale #TheHumanTrial #StorycomicPresents #MedicalThriller #HarvardMedicine #HistoricalFiction #MedicalEthics #ScienceFiction #AuthorInterview #BookTalk #NewReleases2024 #Pathology #MedicalHistory #ThrillerBooks #WomenWriters Welcome to Storycomic Presents! In Episode 384, join us as we delve into the riveting world of medical thrillers with nationally celebrated author Audrey Gale. In this exclusive interview, we explore her latest novel, "The Human Trial," a gripping narrative set in the historic halls of Harvard's Medical Laboratory. Discover the journey of Randy Archer, a soon-to-be Harvard-educated pathologist, as he navigates the complexities of groundbreaking scientific discovery alongside personal and ethical dilemmas. Audrey Gale shares insights into her creative process, the historical and scientific research that informs her writing, and the personal experiences that fuel her narratives. Tune in to uncover the depths of medical science and the personal trials that shape her characters' lives. The Title sequence was designed and created by Morgan Quaid. See more of Morgan's Work at: https://morganquaid.com/ Storycomic Logo designed by Gregory Giordano See more of Greg's work at: https://www.instagram.com/gregory_c_giordano_art/ Want to start your own podcast? Click on the link to get started: https://www.podbean.com/storycomic Follow us: Are you curious to see the video version of this interview? It's on our website too! www.storycomic.com www.patreon.com/storycomic www.facebook.com/storycomic1 https://www.instagram.com/storycomic/ https://twitter.com/storycomic1 For information on being a guest or curious to learn more about Storycomic? Contact us at info@storycomic.com Thank you to our Founders Club Patrons, Michael Winn, Higgins802, Von Allan, Stephanie Nina Pitsirilos, Marek Bennett, Donna Carr Roberts, Andrew Gronosky, and Matt & Therese. Check out their fantastic work at: https://marekbennett.com/ https://www.hexapus-ink.com/ https://www.stephanieninapitsirilos.com/ https://www.vonallan.com/ https://higgins802.com/ https://shewstone.com/ https://mrfuzzyears.com/ Also to Michael Winn who is a member of our Founders Club!
Author Audrey Gale joined me to talk about her medical thriller, research, medicine, the importance of a writing community, her writing experience and more. Enjoy! Find out more about Audrey: https://audreygaleauthor.com If you like what we do, you might consider buying us a coffee. You can do so here: https://www.buymeacoffee.com/booklovercom or here: https://ko-fi.com/bookcompanion You can also support us via Paypal: https://www.paypal.com/paypalme/bookcompanion or via Patreon: https://www.patreon.com/bookcompanion Follow us: Web: https://book-lovers-companion.com Twitter: https://twitter.com/book_companion Facebook: https://www.facebook.com/ez.fiction.7/ Instagram: https://www.instagram.com/book_companion/ Youtube: https://www.youtube.com/channel/UC6vyAyrh3zzsxNeexfyU0uA Feedback is always welcome: bookcompanioncontact@gmail.com Music: English Country Garden by Aaron Kenny Video Link: https://youtu.be/mDcADD4oS5E
A lesser-known cannabinoid known as CBG has surprised scientists after a first-ever human clinical trial found that it appears to improve memory, while also “significantly” reducing anxiety and stress. The non-intoxicating cannabinoid might not be as well-known as THC and CBD, for example, but as it's grown in popularity, researchers at Washington State University (WSU) and the University of California at Los Angeles (UCLA) set out to investigate its therapeutic potential amid anecdotal, survey-based reports about its therapeutic potential. The study, published in the journal Scientific Reports this month, found that cannabigerol, or CBG, caused a “significant overall reductions in anxiety as well as reductions in stress” among study participants compared to the placebo. “CBG also enhanced verbal memory relative to placebo,” with “no evidence of subjective drug effects or impairment.” Cannabis Talk 101, “The World's #1 Source For Everything Cannabis”, made global history by becoming the first cannabis show to partner with iHeartMedia, on 4/20/2020. Thank you for listening & watching Cannabis Talk 101 with Christopher Wright, aka "Blue" the CEO and creator of Cannabis Talk 101 and the Cannabis Talk Network. & Joe Grande, former Co-Host on Big Boy's Neighborhood on Power 106 FM, On-Air with Ryan Seacrest on 102.7 KIIS FM in Los Angeles and The Dog House in the Bay Area on WILD 94.9 KYLD. FOX SPORTS, NBC SPORTS. Financial Fridays with Tony Kassaei, The Inside Investor, 40 TONS TALK, WITH ANTHONY SLIMBURG, CHRONIC HISTORY WITH HISTORY CONNOR V. Toking with the Stars with Chuckie & Marty, & on YouTube, IHeartRadio App, Spotify, & Apple Podcasts. See omnystudio.com/listener for privacy information.
**Mark Your Calendar!** Today we serve T-E-A together to make a difference. **Meet My Guest: Audrey Gale** **Author of “The Human Trial”**Audrey Gale **Date:** August 22nd **Time:** 3 PM ESTJoin us for a riveting conversation with Audrey Gale, author of the medical-thriller trilogy “The Human Trial.” Discover her transition from banking to writing and her mission to shake up traditional medicine. **Watch/Listen on Multiple Platforms!** Visit [audreygaleauthor.com](http://audreygaleauthor.com/) for more!#TeatimeWithMissLiz #AudreyGale #TheHumanTrial #AuthorInterview #BookTalk #LiveStream #Podcast #MedicalThriller #BookLovers #WomenAuthors #healthinnovation
In this episode, we sit down with Audrey Gale, an acclaimed author renowned for her exploration of suppressed scientific knowledge and its impact on healthcare. Audrey, who transitioned from a successful two-decade career in banking to become a passionate writer, shares her unique journey and the challenges of integrating groundbreaking scientific discoveries into her novels.With a master's degree in fiction writing from the University of Southern California, Audrey has crafted a compelling medical-thriller trilogy, starting with "The Human Trial." Her works delve into the fascinating intersection of traditional medicine and revolutionary scientific breakthroughs, aiming to shed light on treatments that could redefine health and wellness.Audrey's insights are not just about storytelling; they are a call to action for listeners to proactively question and understand the healthcare options and scientific advancements available to them. Tune in to discover how her books address the often-suppressed aspects of science and how her experiences inspire a more informed approach to modern medicine.In this episode, we cover:Audrey Gale's Transition: From a successful banking career to becoming an accomplished author.Medical-Thriller Trilogy: Insights into her series starting with "The Human Trial" and its exploration of suppressed scientific breakthroughs.Intersection of Medicine and Science: How her novels integrate traditional medicine with groundbreaking scientific discoveries.Inspiring Curiosity: Encouraging listeners to question and understand healthcare treatments and scientific advancements.Challenges and Rewards: The obstacles and triumphs of bringing hidden scientific knowledge to light through writing.Sarah asks our listeners: What is a healing event from a non-traditional approach that you've had? What is a key takeaway here that you resonate with the most? PLEASE SHARE!Don't miss this enlightening conversation with an author whose work challenges conventions and seeks to inspire curiosity about the science shaping our future.Free Gift: Discounted book @ https://audreygaleauthor.com/Connect and Learn more with Audrey here:Website: https://audreygaleauthor.com/Instagram: https://www.instagram.com/audreygaleauthor/Facebook: https://www.facebook.com/audreygaleauthorTwitter/X: https://twitter.com/TheAudreyGaleConnect and Learn more with Sarah Boxx @ The SandBoxx offers Nonprofit business consulting and coaching for leaders. (sarahboxx.com)#RIFE #frequencies #NLNL #nontraditional #healing #healthandwellness Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.
The Human Trial with Audrey Gale The Human Trial takes us back to the early 1900s, the dawn of quantum physics—when Niels Bohr and Albert Einstein were unwrapping the relationship between light, vibration, and matter. The book begins in 1921, when a brilliant but impoverished 16-year-old, Randy Archer, gets an unexpected fully-paid scholarship to Harvard Medical School, beginning his incredible, but challenging, rise to becoming the groundbreaking pathology researcher that he dreams of becoming. Coming from the background of a steel-mill worker's son to the blue-blooded hallways of Cambridge, he is viewed as an outsider—the one who doesn't belong. This powerful thriller, which speaks to all those who question medical- or establishment-interference in our lives that blocks innovative, energetic lifesaving modalities, This is Audrey Gale's second novel. After 20 years in the banking industry, she walked away from corporate gamesmanship to fulfill her dream of being a writer. She then pursued a master's in fiction writing at the University of Southern California To learn more about Audrey visit: audreygaleauthor.com *************************************************** For more information about BITEradio products and services visit: http://www.biteradio.me/index.html To view the photography of Robert at: http://rpsharpe.com/
Here Dr Reis talks about the human as well as in vitro trials that her company is doing. The papers can be found on the OneSkin website (including the one that she refers to in the video as being published in the next week) Dr. Carolina Reis is the co-found and CEO of OneSkin Technologies. She holds a biochemistry degree and a Ph.D. focused on stem cell and tissue engineering. After more than 10 years of developing science in academia, she is thrilled to translate basic science into products that will extend our healthspan. As a founder of OneSkin, she and the team have been working to develop the first anti-senescence topical product designed to promote skin health from within. Dr. Reis is an alumnus of IndieBio, the world's largest seed biotech accelerator. She has moved from Latin America to Silicon Valley 4 years ago to found OneSkin and has been actively engaged in the longevity ecosystem in the Bay Area.
Not everyone loves a deep chat as much as I do, but documentary film maker Lisa Hepner really went there with me as we plunged the depths of the rollercoaster that is type 1 diabetes, in an episode I've been thinking about eve since we recorded. In a way I felt like I was speaking to someone I already knew. Lisa knows more about type 1 diabetes than most. Not only has she lived with the condition since she was diagnosed in 1991 aged 21, she spent over a decade filming, writing, directing and producing The Human Trial - a film that closely follows the progress of a radical stem cell trial hoping cure type 1 diabetes for good. As heart-wrenching as it is inspirational, The Human Trial follows the personal journeys of both the patients and the researchers who risk everything to go first, in a bid change the future for all of us living with this condition. It left me deeply confronted and incredibly hopeful, and in this episode we get the inside story. WATCH THE HUMAN TRIAL:The Human Trial website.Watch The Human Trial on Prime Video.Watch The Human Trial on Apple TV.Follow The Human Trial on Instagram. JOIN THE TYPE 1 ON 1 COMMUNITYWe've got an Instagram account! Come and say hi @studiotype1on1SPONSOR MESSAGE:Thanks to my episode sponsors Insulet, the founders of Pod Therapy - only found with Omnipod. Pod Therapy uses a tubeless, wearable and waterproof Pod that continuously delivers insulin for up to three days. Controlled wirelessly by its handheld companion, it allows you to personalise your insulin doses according to your own daily needs - no multiple daily injections and no tubes. Head to https://www.omnipod.com/ to find out more.
Inside Neuralink's First Human Trial !! | ep: 240 | Tamil podcast | #neuralink #elonmusk #brain
In this freewheeling episode of Techcetra, hosts - Shouvik, Leslie and Deepti - discuss recent research from the University of Milano on how smartphone usage adversely affects young children when it comes to linguistic abilities. To correct such issues developed over a while, they then speak of Elon Musk-owned Neuralink and its 1st human trial. Amongst the pros, the hosts state how this invasive brain-computer interface might go a step ahead and be able to help people like Stephen Hawking. Finally, having discussed how Gen Z perceives information differently and having agreed upon how new technologies have always had the power to rewire our brains, they shift our attention to the newly released economic review by the Indian Finance Ministry. They marvel at how the Indian government is unique in stating the advantages and disadvantages of AI on employment. While Shouvik underlines how AI will contribute to 30% of India's 5 trillion economy goal, he also quotes the IMF study which suggests that 40% of the global economy is exposed to AI. At the same time, Leslie reminds us that about 90% of India works in the unorganized sector which might remain unaffected for the time being when it comes to job losses. Here, Deepti quotes Mr. Umakant Soni, Chairman of AI Foundry from a recent AI Rising episode. She highlights how data and desperation will be the 2 deciding factors for India's economic standing in the years to come. Tune in to gain an insight into your present so you can have agency over your future. And if you enjoyed listening to this episode then tune in to the recent AI Rising episode here: https://ai-rising-podcast.simplecast.com/episodes/india-is-the-supermarket-of-problems-building-ai-ecosystem-on-data-desperation
For the 850 million people around the world suffering from chronic kidney disease, the grind of dialysis treatment can wear them down in more ways than one. Dr. Andy Herbert, co-founder of Invizius, is out to change that. This five-year-old company started from humble beginnings and is currently developing H-Guard® Priming Solution, which increases the effectiveness of dialysis while negating, or eliminating, its potentially dangerous side effects. It will be used in an upcoming first-in-human clinical trial and has the potential to improve patients' quality of life – both physically and mentally. Join Dr. Herbert as we discuss the origins of Invizius, how H-Guard works, why dialysis can take a toll on mental health, and how working with a strategic partner has helped Invizius progress this treatment.Show Notes Invizius Charles River's Nonclinical Support Helps Invizius Secure MHRA Approval for First-in-Human Trial of H-Guard® Hemodialysis Solution Renal Disorders | Charles River Preclinical CRO Services for Safety Assessment Inflammation | Charles River
In her Depression-era thriller “The Human Trial,” author Audrey Gale shares the story of Dr. Randall Archer, who changed medicine forever with his groundbreaking microscope. Overnight, he's catapulted from the steel mills to the upper echelon of Bostonian society. But many challenges await, from the devastation of the Great Depression to the battle to maintain his place. In this episode, Curtis and Max talk with Audrey about what inspired this book and the creation of Archer. We look at her own experience with medicine and how this shaped the novel, as well as the research done. Audrey talks about Archer's ascension and how this impacts him, as well as how he has to fight to keep what he's earned.
The clever way one developer hacked an online game, why we're not buying the latest round of cyber war fear, and we finally have our Babylon 5 vs Star Trek debate.
Joining us today is Audrey Gale, the author of The Sausage Maker's Daughters, and most recently, The Human Trial. Audrey has always dreamed of becoming an author, and after spending more than 20 years in the banking industry, she left the corporate world behind to pursue her true passion – and hasn't looked back since… Audrey pursued her master's in fiction writing at the University of Southern California. Since then, she has focused her efforts on exploring historical and scientific research through her writing, and always includes women finding their places in the scope of the storyline. In this episode, we discuss: What The Human Trial is about, and how Audrey created the concept. How quantum physics made its way into Audrey's book. Why Audrey decided to incorporate quantum physics into her writing. Future novels on the horizon. Want to find out more about Audrey and her work as an author? Click here now! Episode also available on Apple Podcasts: https://apple.co/38oMlMr
This episode of Big Blend Radio features award-winning author Audrey Gale who talks about how she pushes the envelope and abandons tropes in her new Depression-era medical thriller, "The Human Trial." The novel merges three genres: historical fiction, medical thriller, and coming-of-age story, cast with imperfect, relatable characters. WATCH THE PODCAST ON YOUTUBE: https://youtu.be/c3liqSGArAw More: http://audreygaleauthor.com/ Hosted on Acast. See acast.com/privacy for more information.
This episode of Big Blend Radio features award-winning author Audrey Gale who talks about how she pushes the envelope and abandons tropes in her new Depression-era medical thriller, "The Human Trial." The novel merges three genres: historical fiction, medical thriller, and coming-of-age story, cast with imperfect, relatable characters. WATCH THE PODCAST ON YOUTUBE: https://youtu.be/c3liqSGArAw More: http://audreygaleauthor.com/
Here Dr Patel talks about his topical glutathione treatment Glutaryl and the recent trial that was conducted at McGill University. Dr. Nayan Patel is an alumnus of the University Of Southern California School Of Pharmacy, where he now serves as adjunct faculty. A pharmacist for over three decades, Patel is an internationally recognized expert, consultant, and lecturer on the Master Antioxidant Glutathione. Dr. Patel founded Auro Wellness in 2011 to create products to help the body function at an optimal level and reduce the long-term impact of stress on the body. Through his research, Dr. Patel stabilized Glutathione, improved absorption, and increased its effectiveness with the Auro GSH™ Antioxidant Delivery System. He is the author of The Glutathione Revolution: Fight Disease, Slow Aging & Increase Energy, which addresses how powerful and essential Glutathione is to the body's detoxification system and how to increase the body's levels naturally.
Audrey Gale long dreamed of being a writer, but never anticipated the circuitous road she'd take to get there. After twenty-plus years in the banking industry, she grew tired of corporate gamesmanship and pursued her master's in fiction writing at the University of Southern California. She joined me on Uncorking a story to discuss her second novel,The Human Trial, which is the first book in a medical-thriller trilogy inspired by Audrey's own experiences with the gap between traditional medicine and approaches based on the findings of the great physicists of the 20th Century. Key Themes Career Transition: One prominent theme is Audrey's journey from the banking industry to becoming a writer. This highlights the challenges and motivations behind her decision to pursue her passion for writing after spending over 20 years in a different field. Medical Thriller: Another key theme is Audrey's second novel, "The Human Trial," which is the first book in a medical thriller trilogy. We explore the inspiration behind the book, which stems from Audrey's personal experiences with the gap between traditional medicine and alternative approaches influenced by the discoveries of renowned physicists. Personal Inspiration: Audrey discusses how she fictionalizes real discoveries and personal experiences to craft a compelling story. We delve into the creative process behind Audrey's writing and how she draws inspiration from her own life to create engaging narratives. Quantum Biology: The conversation touches upon the theme of exploring a new paradigm, specifically the concept of quantum biology. Audrey discusses the power of quantum biology and its potential impact on understanding life on a deeper level. This showcases Audrey's interest in scientific concepts and how they influence her storytelling. Funding and Priorities in Medical Research: Lastly, the conversation briefly touches upon the theme of funding sources and priorities in medical research. Audrey shares insights into the challenges faced by researchers and the importance of allocating resources to advance medical knowledge and innovation. Buy The Human Trial Amazon: https://amzn.to/3tv6Zs2 Bookshop.org: https://bookshop.org/a/54587/9781953865700 Connect With Audrey Website: http://audreygaleauthor.com/ Instagram: https://www.instagram.com/audreygaleauthor/ Facebook: https://www.facebook.com/audreygaleauthor Goodreads: https://www.goodreads.com/book/show/195947240-the-human-trial Connect with Mike Website: https://uncorkingastory.com/ Youtube: https://www.youtube.com/channel/UCSvS4fuG3L1JMZeOyHvfk_g Instagram: https://www.instagram.com/uncorkingastory/ TikTok: https://www.tiktok.com/@uncorkingastory Twitter: https://twitter.com/uncorkingastory Facebook: https://www.facebook.com/uncorkingastory LinkedIn: https://www.linkedin.com/company/uncorking-a-story/ If you like this episode, please share it with a friend. If you have not done so already, please rate and review Uncorking a Story on Apple Podcasts, or wherever you get your podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices
Here Dr Conlon talks about the human trial that she sponsored to evaluate the benefits of Time+ on humans. Dr Nichola Conlon is a molecular biologist specialising in the study of cellular aging. After a career in drug development, she founded Nuchido Laboratories to deliver disruptive innovation in the field of aging, rejuvenation and healthspan. Dr Conlon has a passion for sharing the latest science and is an accomplished speaker, with a skill for translating advanced science to help educate and support the wider population, encouraging people to age well and achieve their optimal life experience.
In this episode, we sit down with Audrey Gale to discuss her latest novel, The Human Trial. As the second release of her medical-thriller trilogy, this book explores the gap between traditional medicine – while incorporating the findings of the great physicists of the 20th Century… Audrey has always dreamed of becoming an author. Now that this dream has become a reality, she is on a mission to flush out her fascination with historical and scientific research in a thoughtful and engaging way. Tune in now to learn about: The premise of The Human Trial, and what led Audrey to write it. Challenges that can arise while writing a novel. The power of holistic medicine. Other novels that Audrey is looking forward to writing. Want to find out more about Audrey and her work as an author? Click here now! Episode also available on Apple Podcasts: apple.co/30PvU9C
We talk to Dr Colleen Cutcliffe about a clinical trial that they ran with 5 strains of probiotic. We also talk about whether the strains remained resident and what are the best prebiotics for akkermansia.
Audrey Gale long dreamed of being a writer, but never anticipated the circuitous road she'd take to get there. After twenty-plus years in the banking industry, she grew tired of corporate gamesmanship and pursued her master's in fiction writing at the University of Southern California. Her first novel, a legal thriller entitled The Sausage Maker's Daughters, was published under the name A.G.S. Johnson. The novel explores one woman's struggle to find her place amidst the upheaval of the radical 1960s. Her second, The Human Trial, is the first book in a medical-thriller trilogy inspired by Gale's own experiences with the gap between traditional medicine and approaches based on the findings of the great physicists of the 20th Century, like Einstein and Bohr. Both The Sausage Maker's Daughters and The Human Trial incorporate Gale's fascination with historical and scientific research, and always with women finding their places. Gale lives in Los Angeles with her husband and dogs where she is found hiking the Santa Monica Mountains every chance she gets. Make sure to check out this author on Instagram @audreygaleauthor You can listen to the podcast on Apple Podcast, Spotify, Google Podcast, or visit my website www.drkatherinehayes.com
We talk to Dr Vijay Yadav about the human results from the trial and how the dosage might translate into humans. Dr Yadav leads the Systems Biology of Aging Laboratory, which aims to identify novel functional connections between organs and to unravel factors that underlie human metabolism and its disorders. The lab's expertise is in the development of a variety of technologies including mouse genetic (CRISPR/Cas, homologous recombination in embryonic stem cells, iPS cells), genomic (Nucleic acid sequencing), and proteomic (MS/NMR/HPLC). The ultimate aim is to identify novel therapeutic targets for genetic and metabolic disorders to manage these diseases in humans.
Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
In this episode Dr Guttuso talks about two positive random controlled clinical trials of low dose lithium with Alzheimer's and two on going trials. Thomas Guttuso, Jr., MD, is a professor of neurology at the University at Buffalo. He has been treating patients with Parkinson's for over twenty years and has published over thirty articles in leading medical journals. Dr Guttuso recently published the book “The Promise Of Lithium” on the use of lithium supplementation to potentially slow the progression of both Alzheimer's and Parkinson's. He is also currently conducting a placebo-controlled trial in examining the effects of low-dose lithium therapy on long COVID symptoms.
This episode we discuss Lab Grown Blood its first world clinical trial used in humans, the us has reached its debt limit, also who is responsible for the poor Infrastructure in low-income neighborhoods. This Episode is Sponsored by: Prodent Max. An Organic Health Toothpaste made of Natural Ingredients. www.prodentmax.com IG@TwistedYounginz TikTok@TwistedYounginz www.twistedyounginzz.com If you would like to Support or Donate : Cash App $Twistedyounginz
India has a long tradition of different systems of medicine. Medical pluralism looks at integrating these systems with modern evidence-based medicine. Mahek Nankani and Dr. Harshit Kukreja discuss AYUSH, Covid-19 and the potential of India's traditional knowledge. You can follow Mahek Nankani on twitter: https://mobile.twitter.com/maheknankani You can follow Harshit Kukreja on twitter: https://mobile.twitter.com/harshitk43 Check out Takshashila's courses: https://school.takshashila.org.in/ You can listen to this show and other awesome shows on the IVM Podcasts app on Android: https://ivm.today/android or iOS: https://ivm.today/ios, or any other podcast app. You can check out our website at https://shows.ivmpodcasts.com/featured Do follow IVM Podcasts on social media. We are @IVMPodcasts on Facebook, Twitter, & Instagram. https://twitter.com/IVMPodcasts https://www.instagram.com/ivmpodcasts/?hl=en https://www.facebook.com/ivmpodcasts/ Follow the show across platforms: Spotify, Google Podcasts, Apple Podcasts, JioSaavn, Gaana, Amazon Music Do share the word with your folks!See omnystudio.com/listener for privacy information.
This episode of BEHIND THE LENS is a fascinating conversation with director LISA HEPNER and director of photography GUY MOSSMAN as they talk about their new documentary – THE HUMAN TRIAL. Plus, my exclusive interview with writer/director MALI ELFMAN going in-depth talking her feature directorial debut, NEXT EXIT. Joining us live during National Diabetes Month are director LISA HEPNER and director of photography GUY MOSSMAN talking about THE HUMAN TRIAL. Herself a diabetic, this is a very personal project for Lisa. Already an established producer, Lisa moves into the director's chair to take us into the up close and personal world of human clinical trials for a treatment for Type 1 Diabetes. Listen as Lisa and Guy talk about the 7+ year journey of making this documentary, starting with researchers and a biotech company in San Diego, then filming the arduous roller coaster ride of the first two patients in the clinical trial with the good, the bad, and the heartbreaking pain and tears, while also travelling around the globe with the biotech reps seeking much-needed funding to continue research. But first, you'll hear our exclusive interview with writer/director Mali Elfman as we discuss NEXT EXIT! I have had the privilege and pleasure of knowing Mali for about two decades now. It has always been her goal to "make movies" versus "cover movies". For some years now she has been producing projects that range from episodics to shorts to anthologies to features; she's written some shorts and directed a few shorts and episodics. Always consistently honing her craft, she now makes her feature directorial debut with NEXT EXIT. Also written by Mali, the story has powerful themes surrounding grief, life, and death, that give rise to thought and discussion and even some interpersonal reflection, all showcased within a road picture setting (and the road trip in the film is real) boasting wonderful performances – and humor – courtesy of Katie Parker and the scene-stealing Rahul Kohli. An award-worthy first feature, this is a film and a conversation you don't want to miss as we hit the road into the "making of" NEXT EXIT. http://eliasentertainmentnetwork.com
While taking a proactive approach to wellness is always preferred, not everyone has that luxury. For some, taking control of your own well-being is a matter of life or death—as it is for the millions of people suffering from type 1 diabetes (T1D). No matter what their lifestyle, the body of a type 1 diabetic will never naturally produce insulin. In 2021 alone, 6.7 million people died from diabetes—that's the population of Madrid. What will it take to ease the burden on so many and support research to find a cure once and for all? Documentary filmmaker Lisa Hepner set out to find the answer. Along with her husband Guy Mossman, they created the new film “The Human Trial,” a movie over ten years in the making that explores the human side of research and the people behind it. While on the path to curing her own type 1 diabetes, Lisa was given unprecedented access to a real clinical trial involving stem cells. After her own 30-year struggle with diabetes and always hearing the cure was five years away, she decided to take things into her own hands. The documentary follows her own intimate journey in real-time, along with the other patients and scientists involved, to be the first to give this cutting-edge and ultimately uncertain treatment a try. Most of us don't have to consider the mental toll of type 1 diabetes. Not only do patients need daily injections to keep them alive, but they have to consider every potentiality to ensure they are never without access to this life-saving necessity. And that's if they can afford them: One in four Americans ration their insulin because they can't afford to use it as often as needed. While technology has come a long way in easing the burden, such as continuous glucose monitors being able to read blood sugar levels every few minutes and beam them directly to your phone or smartwatch, the process is still frustratingly manual. And T1D is one of the only diseases where the patient plays such a large role in treating themselves, which speaks to how far our healthcare has to go in supporting people with this disease. Ultimately, Lisa says this: “There is hope for a cure.” Research is heading in the right direction, it just needs funding to continue. Despite hearing for over thirty years that we are just “five years away from the cure,” based on what she's seen, Lisa truly believes it is true today. To learn more, visit Lisa Hepner's site at http://thehumantrial.com (TheHumanTrial.com). Resources: https://www.thehumantrial.com/ (thehumantrial.com) Follow Lisa on LinkedIn: https://www.linkedin.com/in/lisa-hepner-a010145/ (linkedin.com/in/lisa-hepner-a010145) Hosted by https://www.swellpublicrelations.com (Kim Marshall).
The month of November is all about diabetes awareness. In this solo episode Pam highlights some of her experiences at the ISPAD 2022 meeting in Abu Dhabi as well as some upcoming initiatives at Diapoint. The theme for Diabetes Awareness Month is Access. Our initiatives and work supports people in getting access to information and supplies, and encourages them to seek out qualified medical support when possible. Whether it's insulin, supplies, information or support, people with diabetes need access to all of these things to manage the condition. We will share more information about our local, Dubai screening of The Human Trial when you are able to reserve your tickets. Join the Diapoint mailing list for exclusive insights and offers: diapointme.com/join-the-diapointme-mailing-list/ Visit the D-Shop where we offer beautiful, practical diabetes supplies and lifestyle accessories: https://www.diapointshop.com/ Home study program for parents of school-aged children with Type 1 Diabetes: https://www.diapointlearning.com/courses/the-ultimate-type-1-diabetes-school-game-plan Diabetes resources: https://www.diapointme.com/diabetes-wellness-resources/ Diapoint is the place for people touched by diabetes. For more information and full details of our work, visit diapointme.com where you'll also find our social media links and any resources mentioned in the episode. Subscribe to the podcast so you get notifications for all our episodes, and please share it on social media or with anyone you think could benefit from this free content.
Filmmaker Lisa Hepner, who has type 1 diabetes, goes behind the scenes in her documentary, "The Human Trial", to meet the people who put their lives on the line to test experimental drugs. She spoke to Andrew Carter.
In June 2022, The Human Trial documentary film was released by writer and director, Lisa Hepner who was given unprecedented access to participants in the sixth ever embryonic stem cell trial in the world. Behind every breakthrough are those who risk everything for everybody else. In this episode we get into the hard hitting details […]
In June 2022, The Human Trial documentary film was released by writer and director, Lisa Hepner who was given unprecedented access to participants in the sixth ever embryonic stem cell trial in the world. Behind every breakthrough are those who risk everything for everybody else. In this episode we get into the hard hitting details […] The post #126: Lisa Hepner | The Human Trial appeared first on Diabetes Daily Grind | Real Life Diabetes Podcast.
The Human Trial is a documentary from filmmakers Lisa Hepner and Guy Mossman that follows a human clinical trial using embryonic stem cells over the course of seven years as researchers and patient volunteers work on a cure for type 1 diabetes. The filmmakers gained unprecedented access to the San Diego biotech start-up ViaCyte which has developed an implantable pouch that holds stem cells programmed to create the kind of insulin-producing pancreatic islet cells destroyed by type 1 diabetes. It is considered one of the most promising paths to a functional cure for the disease.During this podcast, Lisa Hepner, who has type 1 diabetes, discusses what she learned during the filming of the documentary. She talks about the process of gaining the trust of both researchers and patients as they experience elation and disappointment. And she reveals her view on if and when researchers will develop a cure for type 1 diabetes.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
OKYO Pharma's Gary S. Jacob talks to Proactive's Katie about its collaboration with US group AmbioPharm on an investigational new drug (IND) filing of dry eye disease (DED) treatment OK-101. A US IND filing is expected in the final quarter of 2022, OKYO reiterated today, with a first human trial scheduled for early in 2023. Jacob explains how beneficial it is to be able to skip straight on to a phase 2 trial, 'leap frogging' the normal phase 1 study, as the drug is administered topically.
It's in the news! The top stories and headlines around the diabetes community this week include new progress in the quest for oral insulin to treat type 1, a new study says a common type 2 diabetes drug may help those with serious heart condition, a look at teen brains and T1D, NSAID and type 2 and more! Learn about the T1d Exchange: www.t1dexchange.org/stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story.. very early on here, but some progress in oral insulin for type 1. A team at University of British Columbia has developed a different kind of tablet that isn't made for swallowing, but instead dissolves when placed between the gum and cheek. This method delivered all the insulin to the liver without wasting or decomposing any insulin along the way. That's a big change from earlier studies and methods. The oral tablets absorb after about half an hour and last for up to four hours.. long way to go, no human trials yet. The the lead researcher on this project has a father with type 1 . https://www.sciencedaily.com/releases/2022/08/220830093215.htm?fbclid=IwAR1AzjI5UJma9I6g4hST044FS0MbJnUA0EXCmKXyhcOiOKL-ckIQTO4h8dY XX The type 2 diabetes drug dapagliflozin might also be used to help people with heart failure. A new study at Brigham and Women's Hospital showed that dapagliflozin – sold under the brand name Farxiga - reduced the risk of a cardiovascular death, or worsening heart failure, regardless of ejection fraction. Ejection fraction is a term that basically refers to how much blood is pumped out by the left ventricle of the heart each time it contracts. That's important because this drug has already been shown to help people who have the reduced pumping. And that's a lot more people. Big study here, more than 12-thousand people with lots of ages and races, benefits consistent throughout. https://www.bostonglobe.com/2022/08/29/business/brigham-womens-researchers-say-diabetes-drug-helps-reduce-heart-failure/ XX I hesitate to bring this study up, but it's gotten a lot of attention this week. It shows tight control of blood sugar in teens with Type 1 diabetes may help reduce the disease's damaging effects on the brain. But this small study from Nemours Children's Health, Jacksonville and Stanford University School of Medicine didn't release any numbers, n other words, it's not clear what they mean by tight control or at what level they're referring to for brain issues. Their findings to indicate that automated hybrid closed loop systems work really well and that better glucose control can actually improve brain structure and function in teens with type 1. I've reached out to this group and we're working on getting more information in a future episode. https://neurosciencenews.com/blood-sugar-brain-diabetes-21328/ XX Very early on here.. but an Indiana startup says they have a potentially game changing type 1 drug in development. In T1D, the body's immune system causes destruction of beta cells, and as a result, they eventually stop producing insulin. These researchers say their models show thy can take what were thought to be dead beta cells, which are actually sleeping beta cells, and increase their insulin secretion and, basically, get them back to a functional state.” They're focusing on a calcium imbalance within the beta cell and designing molecules to correct that calcium imbalance, ultimately returning the pancreas to a healthy state. JDRF has given them a big grant for a two year project, hopefully getting them to clinical trials. https://www.insideindianabusiness.com/articles/startup-awarded-nearly-1m-to-advance-diabetes-drug XX People with type 2 diabetes might face a substantially increased risk of heart failure if they take ibuprofen or some other type of nonsteroidal anti-inflammatory drug (NSAID), accord to a new Danish study. Short-term NSAID use increased risk of hospitalization for heart failure by 43% in people with type 2 but no previous heart problems. This was a large but preliminary study presented at the European Society of Cardiology's annual meeting. NSAIDs increased the risk of heart failure even more in type 2 diabetics who were 80 or older (78%) or who had high blood sugar levels (68%), the results showed. Those who'd never used an NSAID before had the worst reaction, with their heart failure risk nearly tripling. Type 2 diabetics should consult with their doctor before taking any pain medicine, the doctors said. Other types of pain meds -- specifically acetaminophen (Tylenol) -- should be safe for them to use. https://www.usnews.com/news/health-news/articles/2022-08-24/certain-painkillers-raise-heart-failure-risk-in-people-with-type-2-diabetes XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX We told you about The Human Trial, Watch this gripping new documentary about the brave men and women who volunteer to test a radical new treatment for type 1 diabetes. n 2011, Lisa Hepner and her husband Guy Mossman heard about a radical stem cell treatment for diabetes, a disease that shockingly kills more than five million people each year. Driven by a desire to cure Lisa of her own type 1 diabetes (T1D), the filmmakers were given unprecedented, real-time access to a clinical trial — only the sixth-ever embryonic stem cell trial in the world. What follows is an intimate journey with the patients and scientists who put themselves on the line to be first. Now, in partnership with Beyond Type 1 & JDRF , they're offering the film for free. You are urged to make a donation to JDRF when you click over, there is an option to select zero, https://watch.showandtell.film/watch/the-human-trial-beyond-type-1 XX Next week we've got a great episode all about Omnipod 5 in the real world. I spoke to a panel of moms and a young adult using the system. And we've got Insulet's Director of Medical affairs addressing the questions that come up. This past episode is with my son Benny, talking about what it was like to spend 8 weeks away at non diabetes camp without any remote monitoring from us. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Director, Writer, and Producer Lisa Hepner sits down with Jan Price to discuss her new documentary, "The Human Trial," – streaming online and playing in select theaters!In 2011, Lisa Hepner and her husband Guy Mossman heard about a radical stem cell treatment for diabetes, a disease that shockingly kills more than five million people each year. Driven by a desire to cure Lisa of her own type 1 diabetes (T1D), the filmmakers were given unprecedented, real-time access to a clinical trial -- only the sixth-ever embryonic stem cell trial in the world. What follows is an intimate journey with the patients and scientists who put themselves on the line to be first. See acast.com/privacy for privacy and opt-out information.
Filmmaker/distributor/producer Ira Deutchman returns to Filmwax to discuss his latest documentary "Searching for Mr. Rugoff" about indie pioneer distributor/exhbitor Donald Rugoff. And filmmaker Lisa Hepner discusses making her documentary "The Human Trial" about the search for a blue for diabetes and her own experience as a survivor of the disease.
Top stories in this news this week: Stem cell research Vertex company buys Viacyte, another company looking at stem cells for a functional cure for T1D, some tslim users are getting access to Tandem's new mobile bolus feature, One Drop shows a "health sensor" on its website, a study shows that screening for type 1 at very young ages could help detect most cases and much more! Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story this week, Vertex buys Viacyte! For context, Vertex is the company that got all the headlines last fall – big article in the New York Times for a stem cell therapy that brought one person with type 1 off insulin completely. The FDA put them on hold but lifted that just last week. Vertex previously acquired Dr. Doug Melton's Semma. Viactye is the company featured in the documentary "The Human Trial" - they're using CRISPR technology to keep the body from rejecting their stem cells. Both companies technology does NOT require immunosuppressive drugs and both say they are working toward a functional cure. Some experts are saying this will speed up that effort while critics worry that it eliminates the competitive aspect of the race. Sernova is still one separate company that has shown stem cell therapy can work.. I've got requests out to Viacyte to talk to us about all of this, so stay tuned. https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-viacyte-goal-accelerating-its-potentially?fbclid=IwAR15qlFSBsBR89blzXymyIGL3tW5C64QtdHpwq7a5fdjmv2q6JmfoTIpm-k XX If we widely screened kids for type 1 at certain ages, a new study suggests, it would identify most of those who go on to develop it by their teen years. These researchers looked at screening for the type 1 autoantibodies at ages 2 and 6. This included nearly 25-thousand children from Europe and US. One issue in this study, funded by JDRF, all the participants in the combined dataset had genetic risk factors for the disease or a relative with type 1 diabetes, in whom performance is expected to be higher. It also included almost exclusively kids of northern European ancestry. https://www.medscape.com/viewarticle/976992 XX Tandem bolus by phone is slowly rolling out. This week, the T:Connect app was updated in the The t:connect app was updated and emails started arriving for those notified they were part of the early release groups. I did see some reports of people not yet getting the email but seeing the update in their portal so be sure and check. Mobile Bolus is reportedly available for those using Control IQ and Basal IQ. It's worth noting that for those outside the US there really is no timeline, but Tandem has previously said they're going to replace t:connect with a new system that will debut outside the US first. By the way, I got my email this morning, but Benny is still at camp for three more weeks so it'll be a bit before we do the update! XX Interesting look at teens and young adults with type 1.. the early morning psychosocial state may explain a proportion of their daily variance in time in range. The study included 88 participants aged between 14 and 26 years, 56-percent of whom were women. This is tough to quantify but they had the participants complete an engagement prediction survey and set a diabetes management goal for the day when they woke up, and also completed an evening survey. These questions were about mood, motivation, control beliefs, social support, stress, general health, self-esteem, and perceived need for assistance. Of note, lower morning glucose levels correlated with measures of good sleep, high motivation, and good health, whereas higher morning glucose levels were associated with illness and feeling the need for support. https://www.medwirenews.com/diabetes/morning-mindset-daily-glucose-fluctuations-young-people-diabetes/23255450 XX Good catch by our friend Nerdabetic over on Twitter.. One Drop plans to enter what they're calling the continuous health sensing market with a daily disposable, minimally invasive biosensor in development. They say this is designed to provide greater flexibility and insights for people living with diabetes compared to blood glucose monitor (BGM) fingersticks alone. The availability of our continuous health sensor is subject to receipt of clearance or approval from the U.S. Food and Drug Administration. Pending regulatory approval and commercial adoption, we believe integrating the One Drop health sensor with our existing digital solution, One Drop Premium, should augment proven outcomes and yearly cost savings for members living with diabetes and other chronic conditions. https://onedrop.today/blogs/blog/bgm-vs-cgm?utm_source=twitter&utm_medium=social-organic&utm_campaign=social-campaign_jul-2022&utm_content=blog XX Navitus Health Solutions, which is owned by Costco & SSM Health – has joined CivicaScript as a founding member. CivicaScript was created in 2020 to bring affordable versions of common but high-priced generic medicines to market. Earlier this year they announced they would be adding insulin to that list, but it likely won't be available for at least two years. This partnership would seem to insure the lower cost insulin will be available at Costco pharmacies, which you don't have to have a membership to use. https://www.businesswire.com/news/home/20220713005349/en/Navitus-Health-Solutions-Joins-CivicaScriptTM-to-Further-Availability-of-Lower-Cost-Generic-Medications/?fbclid=IwAR0vBF0YlCo9ZJ-9Yd0nLag_Mjuf8s4YpnR9IJVudvVGDR1Rj508HSd_kXw XX Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX The Food and Drug Administration received more than a thousand comments—mainly from diabetes patients and their family members—in response to draft cybersecurity guidance. These are for staff to use when processing submissions from medical-device manufacturers. “Please do not let medical device manufacturers use cybersecurity as a pretense to prevent me from accessing my OWN devices,” reads one entry from a sample of the comments FDA posted to the docket on the guidance. Howard Look, CEO of Tidepool is quoted in some of the article around this. Tidepool provides software that allows patients to see their data and better manage the disease. And supporters are working to make Tidepool Loop the first FDA approved app for more convenient automated insulin delivery. “Following best practices for cybersecurity does not need to imply blocking patient users from accessing their own data or controlling their own devices,” the comments read. “Tidepool asserts there is a risk that the FDA guidance will be interpreted or misinterpreted to suggest restriction of access by the patient user is appropriate or encouraged. The FDA can mitigate this risk by clearly stating a patient user's access to and use of their own device can be considered authorized access, and should not be considered a cybersecurity threat.” With a 90-day public comment period ending Thursday, the FDA will now begin the process of finalizing cybersecurity guidance for its pre-market submissions, according to a notice in the Federal Register. https://www.nextgov.com/cybersecurity/2022/07/diabetes-patients-flood-fda-comments-cybersecurity-medical-devices/374020/ XX Congrats to the team over at Divabetic Podcast – which celebrates 12 years this month! Divabetic was inspired by the late R&B legend, Luther Vandross, and founded in 2005 by his long-time assistant, Max “Mr. Divabetic” Szadek. It's now a national nonprofit organization that uses highly engaged, non-traditional virtual programs, videos and podcasts to promote prevention, early action and education. Congrats to Max and the entire team! https://divabetic.org/about-us/ XX Next week you'll hear from the folks at Diabetes Wise – that's a website to help you choose diabetes technology.. they've added information for doctors – this may help you educate your heathcare providers on why you want the pump or cgm system that you do.. the long format episode out right now is all about campviews, a new system that lets diabetes camps see every camper's CGM all at once. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Top stories in the news this week: researchers are testing an injection to help prevent type 1 diabetes while not harming the immune system, a new study looks at older adults and CGM use, help for pharmacists when it comes to prescribing CGM and a new group takes over the Lilly Diabetes Journey Award Medals. Plus, amazing feats of endurance from ultra athletes with type 1 diabetes. Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Interesting new study looking at preventing type 1. The drug, currently known as IMCY-0098, blocks the immune system response that is thought to be the trigger. Very early on here, the Oxford scientists who are part of the study say it will likely be at least ten years before they'll be able to bring it to market, if it works. One of the most promising aspects is that the injection seems to only target production of cells that damage the immune system, so it doesn't seem to affect the body's ability to protect itself against other infections. https://www.dailymail.co.uk/health/article-10952755/Type-1-diabetes-stopped-strikes-thanks-simple-jab.html XX No surprise but glad this is being looked at. Older adults with type 1 diabetes using CGMs for the first time had lower A1Cs AND fewer lows. This study called WISDM - Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) followed adults over 60 for six months. These researchers say the benefits of CGM combined with recently improved Medicare coverage should serve to increase adoption of CGM as standard of care in all adult populations, especially older people who are at increased risk of hypoglycemia. https://www.healio.com/news/endocrinology/20220627/cgm-improves-time-in-range-reduces-hba1c-for-older-adults-with-type-1-diabetes XX New resource thanks to the Helmsley Trust. This is for pharmacists and it's hoped it will expand patient access to CGMs. The release says Involving pharmacists in providing access is especially important for rural communities where they may be the most reachable healthcare professionals given the lack of diabetes specialists across the U.S. The guide was developed by the American Pharmacists Association and its Foundation http://ow.ly/zZ3c50Jz20f XX Looks like the Lilly Diabetes Journey Award Medals are getting a second life. As we reported back in January, after nearly 50 years, Lilly decided to end the program which gives a small medal for 10,25, 50 and 75 years of living with diabetes. The group Children with Diabetes – best known for putting on the Friends for Life Conference has taken it over. They'll now be called the CWD Journey Awards. You don't have to attend one of their conferences to get one and there is no cost. I'll give you the link to learn more and order one. XX The vets and keepers at the Royal Zoological Society of Scotland (RZSS) diagnosed the first reported case of diabetes in a giant anteater. Stephanie Mota, resident veterinary surgeon at RZSS said: “Keepers first discovered something was wrong when Nala was losing weight despite eating the same amount, or sometimes even more, than usual. “We carried out a full health check under general anaesthetic, running lots of tests and found that Nala has type 1 diabetes.” While the condition is known to occur in domestic cats, dogs and in tamanduas (Tuh-man-doo-uhs) in the wild, no other cases have been reported in giant anteaters. BTW a Tu-man-doo-uh is a smaller anteater and I spent far too much time today watching videos of them because I had never head of them and they are amazing. Dexcom donated the CGM to the Zoo's charity. The story I read here says. Due to her lovely personality, Nala is the ideal candidate for this technology which helps us, and her amazing team of keepers, manage her condition in the best possible way. https://www.edinburghnews.scotsman.com/news/people/edinburgh-zoo-monitor-uks-first-diabetic-giant-anteater-with-blood-glucose-monitor-usually-used-on-humans-3749422 XX Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX Some great stories from our amazing community. First, Sebastien Sassevile completed the world's toughest ultra-cycling race, the Race Across America. It took 12 days and over 3-thousand miles. Sasseville who lives with type 1 basically spent 20 hours a day on his bike. He's the first person with type 1 to finish this grueling race. -- Don Muchow told us he was going to do it and the 60 year old has finished a 10k swim around Key West. I spoke to Muchow just after his 2021 Disney to Disney run – that's Disneyland in California to Disneyworld in Florida and he alluded to doing this race next. I've linked up his race report blog.. it's a very interesting read, especially how he treated a high blood glucose with more carbs. He came in second overall and first male in any age group. https://swimswam.com/60-year-old-iron-man-don-muchow-swims-around-key-west-for-diabetes-awareness/ https://t1determined.org/event-report-swim-around-key-west-10k/?fbclid=IwAR1U7XdI4_uw9OSe994TKuu7IuYjWC8FwHhby0Pm-RRzDIYAd9pGCMj6AD0 XX And finally, another former guest Dr. Nat Strand who works at the Mayo Clinic debuted a film she made with colleagues. It tells the story of what it is to be Black at Mayo Clinic, in healthcare, in America. Dr. Strand says, “By providing a platform for 12 courageous individuals to share their realities, we hope to move viewers toward active antiracism and start the conversation for many to continue.” XX Next week you'll hear from Katie who started a podcast when she didn't hear the diabetes show she wanted.. that sounds familiar. You may know her online as Sugarmama Podcast. The long format episode out right now is all about the new documentary regarding stem cell research, talking to the director of “The Human Trial” i Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
This summer we get a behind the scenes look at the evolution of stem cells as a functional cure for type 1. The Human Trial is new documentary that follows the process and the filmmakers are incredibly optimistic about what they've seen. Co-director Lisa Hepner lives with type 1. She's says she's knows to be careful about “the cure in five years' kind of statements but is convinced this is the real deal. We'll talk about the the film, the process, the science and a lot more. Listen to our first interview with Lisa Hepner from 2016 This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*
It's “In the News..” got a few minutes? Get caught up! Top stories this week: The US Senate may have a bipartisan plan to lower the price of insulin for the insured, nasal insulin is tested to reduce the risk of Alzheimer's in people with diabetes, two interesting studies about sleep and diabetes, and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Two Senators have unveiled legislation aimed at lowering the cost of insulin, but not for the uninsured. This is a bipartisan bill that would lower patietn's cost to 35-dollars a month, for those with commercial insurance and on Medicare. It would eliminate the rebates drug companies pay to negotiators known as pharmacy benefit managers if the drug company kept the overall price of insulin below a certain level. Democrats are also in the midst of talks on a party-line package on President Biden's economic agenda that would likely include reductions in insulin costs as well as broader measures aimed at lowering drug prices, which could complicate any push for a stand-alone insulin measure. This change has enormous support among Americans, but can't seem to get any real traction in Washington despite who's in power. We'll see what happens.. https://thehill.com/policy/healthcare/3531954-bipartisan-pair-of-senators-unveils-bill-to-lower-insulin-costs/ XX Nasal insulin doesn't look like it works too well on diabetes, but a new study shows it may help to slow age related mental decline. This study found that after 12 months of once daily intranasal insulin, people with diabetes in the study performed better on cognitive tests than those diabetics in the placebo group. The non-diabetic group receiving the intranasal insulin also displayed improvements on decision making and verbal memory tests compared to non-diabetics in the placebo group. The biggest improvements in the non-diabetic group were seen in those subjects who started the trial in a prediabetic state. This suggests the treatment may be most effective at slowing cognitive decline in either diabetics or those with prediabetes. https://newatlas.com/health-wellbeing/insulin-nasal-spray-cognitive-decline-dementia-clinical-trial/ XX Go to sleep, and don't breathe too much. Researchers in the U.K. will test hypoxia to treat type 2 diabetes. Hypoxia is a state where the body does not receive sufficient amounts of oxygen. Multiple studies have shown that hypoxia improves blood sugar levels and aids in weight loss. Although scientists do not fully understand how this works, it is suggested that hypoxia burns more calories in the body, resulting in lower appetites in individuals. These researchers want to recruit volunteers so they can figure out why. Each volunteer will be provided with a sleeping tent in which they have to sleep – at home - for 10-day periods on two separate occasions. For one of they nights, they oxygen levels will be set to 15 percent. That sounds ridiculous, but, the air we breathe right now is only about 21% oxygen. 15-percent is pretty typical for find at high altitudes or inside an airplane. https://interestingengineering.com/lose-weight-while-asleep XX Another look at sleeping and type 2.. an exposure to light may increase the risk. Big sleep study at Northwestern University found that exposure to any amount of light during the sleep period was correlated with the higher prevalence of diabetes, obesity and hypertension in both older men and women. A study published earlier this year by the same team found for healthy adults in their 20s. Sleeping for only one night with a dim light, such as a TV set with the sound off, raised the blood sugar and heart rate. An elevated heart rate at night has been shown in prior studies to be a risk factor for future heart disease and early death, while higher blood sugar levels are a sign of insulin resistance, which can ultimately lead to type 2 diabetes. Instead of pulling people into a sleep lab, the new study used a real-world setting. Researchers gave 552 men and women between the ages of 63 and 84 an actigraph, a small device worn like a wristwatch that measures sleep cycles, average movement and light exposure. Fewer than half of the adults in the study got five hours of darkness at night. those who had higher amounts of light at night were also the most likely to have diabetes, obesity or hypertension." Strategies for reducing light levels at night include positioning your bed away from windows or using light-blocking window shades. Don't charge laptops and cellphones in your bedroom where melatonin-altering blue light can disrupt your sleep. If low levels of light persist, try a sleep mask to shelter your eyes. In that case, consider using nightlights positioned very low to the ground, and choose lights with an amber or red color. That spectrum of light has a longer wavelength, and is less intrusive and disruptive to our circadian rhythm, or body clock, than shorter wavelengths such as blue light. https://www.cnn.com/2022/06/22/health/light-exposure-sleep-study-wellness/index.html XX https://medicalxpress.com/news/2022-06-reveals-key-diabetes-drug-nature.htmlXX XX Nice story out of Kansas City where Chiefs offensive tackle Orlando Brown Jr. publicly enrolled himself in a TrialNet study. His brother lives with type 1 and his father died of DKA without knowing he had diabetes. Brown said he hopes participating in the trial will help others while helping himself and his family. https://www.kshb.com/sports/chiefs-orlando-brown-jr-enrolls-in-trialnet-study-for-type-1-diabetes XX Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX Congrats to the great team of Ginger Vieira and Mike Lawson on their newest book. Ain't Gonna Hide My T1D. Sherry the Sheep loves to draw and play basketball, but she's worried about what her friends will think if they see her insulin & CGM. Ginger and Mike are long time advocates who both live with type 1. This is their 3rd children's book together and I think they do a great job of balancing fun and education. https://smile.amazon.com/Aint-Gonna-Hide-My-T1D/dp/B0B455DL45/ref=sr_1_4?qid=1655748198&refinements=p_27:GingerVieira&s=books&sr=1-4&text=GingerVieira XX And finally, The Human Trial premieres this weekend. This is a documentary all about stem cell transplantation as a functional cure for type 1. I first spoke to the people behind this film back in 2016 when they were well underway. The movie follows the first two patients in the Viacyte trials. You can host your own screening.. I'll link up more information – as I do with all of these stories - in the show notes. XX And.. The Human Trial will be subject of next week's long format show. My interview with Lisa Hepner is a follow up to the one six years ago when we first discussed this project. We go into the details of stem cell research, what changed and what she's seen behind the scenes. The current long-format episode out now is all about Skirt My Pump, an ingenious idea from a women who's lived with type 1 for 40 years and got fed up with figuring out where to put her pump. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Welcome back to Hourglass Cinema - a variety show from Victims and Villains. In this episode, we discuss the documentary The Human Trial. The documentary follows the lives of a few individuals who have Type-1 diabetes, their mental health journey and the experimental trials to cure the disease. Captain Nostalgia is joined by Ronald Webster; a friend who has the disease. Hear how this movie impacted him and how gives hope for the future. If you or someone you know is reading this right now and struggling with suicide, depression, addiction, or self-harm - please reach out. Comment, message, or tweet at us. Go to victimsandvillains.net/hope for more resources. Call the suicide lifeline at 1-800-273-8255. Text "HELP" to 741-741. There is hope & you DO have so much value and worth!This episode of Victims and Villains is written by Josh Burkey. It is produced by Josh “ Captain Nostalgia” Burkey. Help us get mental health resources into schools and get exclusive content at the same time. Click here (http://bit.ly/vavpatreon) to support us today!
The Human Trial is a documentary from filmmakers Lisa Hepner and Guy Mossman that follows a human clinical trial using embryonic stem cells over the course of seven years as researchers and patient volunteers work on a cure for type 1 diabetes. The filmmakers gained unprecedented access to the San Diego biotech start-up ViaCyte which has developed an implantable pouch that holds stem cells programmed to create the kind of insulin-producing pancreatic islet cells destroyed by type 1 diabetes. It is considered one of the most promising paths to a functional cure for the disease.During this podcast, Lisa Hepner, who has type 1 diabetes, discusses what she learned during the filming of the documentary. She talks about the process of gaining the trust of both researchers and patients as they experience elation and disappointment. And she reveals her view on if and when researchers will develop a cure for type 1 diabetes.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Topics:Why we haven't posted in a whileThe unfortunate event that happened in a FL amusement parkMale birth control pillBreast feeding in public, normal?Time change can be in the past
Today we talk with Dr. Damon Reed from Moffit Cancer Center and Dr. Nicola Mason from University of Pennsylvania School of Veterinary Medicine about the promising results from a multi-institutional clinical trial evaluating the safety and efficacy of a recombinant Listeria to prevent metastatic disease in dogs with osteosarcoma, and how that will translate to a human trial. #clinicaltrials #osteosarcoma #cancerupdates
The DATA is IN on the largest Human Trial in History...and now it's time to remove the Covid-19 vaccines from the market if saving lives is their true aim.
July 26th, 2021 daily recap of the news headlines.
In this week's episode we touch on the largest intra-African trade transaction completed through blockchain, the ongoing crisis in the town of Palma in Mozambique, a promising vaccine for HIV and we celebrate recent good news that Asteroid Apophis will not hit the earth for another 100 plus years, and not in 2068 as previously thought. Visit the blog (https://taplink.cc/tunukamedia) for pictures and references. © 2021 TunukaMedia
தமிழ் Live with Mashallah Mashallah 1 line song. --- Send in a voice message: https://anchor.fm/tamilminnal/message
Senior Editor Markus Elsner talks to Alex Marson of UCSF about the significance of a Science paper describing the phase 1 clinical trial of CRISPR-engineered T cells. The work was carried out by Carl June and Edward Stadtmauer from UPenn. Read the paper here. See acast.com/privacy for privacy and opt-out information.
© 2020-2025 Ivy Podcast Discovery LLC
